MARKET

GLMD

GLMD

Galmed Pharmaceu
NASDAQ
0.3000
+0.0081
+2.77%
Closed 16:00 12/01 EST
OPEN
0.3000
PREV CLOSE
0.2919
HIGH
0.3060
LOW
0.2905
VOLUME
44.83K
TURNOVER
8.22K
52 WEEK HIGH
2.690
52 WEEK LOW
0.2900
MARKET CAP
7.56M
P/E (TTM)
-0.3322
1D
5D
1M
3M
1Y
5Y
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 09/14 16:00
--Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy
--Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy
MT Newswires · 08/08 08:57
--Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5
--Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5
MT Newswires · 08/08 06:53
--Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5
--Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5
MT Newswires · 08/04 15:56
Galmed Pharmaceuticals: Q2 Earnings Insights
  Galmed Pharmaceuticals (NASDAQ:GLMD) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 08/04 14:00
BRIEF-Galmed Pharmaceuticals Reports Q2 Loss Per Share Of $0.15
BRIEF-Galmed Pharmaceuticals Reports Q2 Loss Per Share Of $0.15
Reuters · 08/04 13:04
Galmed GAAP EPS of -$0.15 beats by $0.09
Galmed press release (<span class="ticker-hover-...
Seekingalpha · 08/04 12:58
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, fibrosis and other fibro...
PR Newswire · 08/04 12:00
More
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.